Table 1. Demographic and clinical characteristics of the subjects.
| Demographics | N (%) Total n = 201 |
|---|---|
| Child Gender Male Female |
100 (49.8) 101 (50.2) |
| Child Race Caucasian African-American |
183 (91) 18 (9) |
| Medication Exposure during Pregnancy | |
|---|---|
| No Antidepressant |
50 (24.9) |
| Any Antidepressant Class 1 (SRIs, SNRIs, TCAs) Class 2 (Bupropion) |
151 (75.1) 132(65.7) 40 (19.9) |
| Atypical Antipsychotics |
32 (15.9) |
| Hypnotics |
31 (15.4) |
| Benzodiazepines |
39 (19.4) |
| Antiemetics | 41 (20.4) |
| Maternal Diagnosis and Symptoms | |
|---|---|
| Lifetime history of MDD Current MDD diagnosis |
146 (72.6) 118 (58.7) |
| Lifetime history of BPD Current BPD diagnosis |
55 (27.4) 50 (24.9) |
| Other Current Diagnoses |
33 (16.4) |
| Maximum Prenatal HRSD17 < 15 ≥ 15 |
178 69 (38.8) 109 (61.2) |
| Maximum Prenatal BDI < 10 ≥ 10 |
179 54 (30.2) 125 (69.8) |
| Prenatal Major Depressive Episode | 86 (42.8) |
*
Data was not available for all measures including 18 missing data points for class 2 antidepressants and benzodiazepine, 20 for atypical antipsychotics and antiemetics, 16 for hypnotics, 23 for HRSD17, and 22 for BDI. The following abbreviations were used: major depressive disorder (MDD), all bipolar disorders (BPD), bipolar disorder 1 (BP1), bipolar disorder 2 (BP2) and other bipolar disorder (BPO). Other current diagnoses included schizophrenia (1), substance abuse (2), anxiety (29), and binge eating (1). Lifetime BPD includes BP1 (78.2%), BP2 (12.7%) and BPO (9.1%), and current BPD has similar proportions.